Linzagolix

Linzagolix is a gonadotropin-releasing hormone antagonist (GnRH antagonist) that is used in the treatment of endometriosis and uterine fibroids. It is developed by ObsEva, a Swiss biopharmaceutical company.

Mechanism of action

Linzagolix works by blocking the gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. This prevents the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn reduces the production of estrogen by the ovaries. The reduction in estrogen levels helps to shrink endometriosis lesions and uterine fibroids.

Clinical trials

Linzagolix has undergone several clinical trials to evaluate its safety and efficacy. The Phase 3 EDELWEISS trial evaluated the efficacy and safety of linzagolix in women with endometriosis-associated pain. The PRIMROSE trials evaluated the efficacy and safety of linzagolix in women with heavy menstrual bleeding associated with uterine fibroids.

Side effects

Common side effects of linzagolix include hot flashes, insomnia, and mood swings. Less common but more serious side effects can include bone loss due to the reduction in estrogen levels.

See also

• Gonadotropin-releasing hormone antagonist
• Endometriosis
• Uterine fibroids

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian